BCL2 and leukemia: Thus, placing the ETV6/RUNX1 transgene under control of the Cd19 promoter may be too late to allow for B cell progenitor leukemia development when combined with BCL2 overexpression, but still allowing to promote autoimmune mature B cell abnormalities that aggravate glomerulonephritis.